{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:09:58Z","timestamp":1790500198643,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["2017\/18488-4"],"award-info":[{"award-number":["2017\/18488-4"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["2018\/03299-0"],"award-info":[{"award-number":["2018\/03299-0"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["2020\/01948-1"],"award-info":[{"award-number":["2020\/01948-1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/P027989\/1"],"award-info":[{"award-number":["MR\/P027989\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/21171-6"],"award-info":[{"award-number":["2016\/21171-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijpddr.2020.08.001","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T21:04:43Z","timestamp":1597439083000},"page":"91-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo"],"prefix":"10.1016","volume":"14","author":[{"given":"Elizabeth M.","family":"Coser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca A.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilson","family":"Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edite H.","family":"Yamashiro-Kanashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Angelo L.","family":"Lindoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0659-6269","authenticated-orcid":false,"given":"Adriano C.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2020.08.001_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ijpddr.2020.08.001_bib2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4269\/ajtmh.2001.65.466","article-title":"Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala","volume":"65","author":"Arana","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib3","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1038\/s41467-019-13344-6","article-title":"Coupling chemical mutagenesis to next generation sequencing for the identification of drug resistance mutations in Leishmania","volume":"10","author":"Bhattacharya","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2020.08.001_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4269\/ajtmh.2008.78.122","article-title":"A real-time polymerase chain reaction assay for the identification and quantification of American Leishmania species on the basis of glucose-6-phosphate dehydrogenase","volume":"78","author":"Castilho","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026660","article-title":"Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani","volume":"6","author":"Chawla","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.ijpddr.2020.08.001_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4269\/ajtmh.2011.10-0155","article-title":"Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil","volume":"84","author":"Chrusciak-Talhari","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib8","doi-asserted-by":"crossref","first-page":"e2999","DOI":"10.1371\/journal.pntd.0002999","article-title":"In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis","volume":"8","author":"Coelho","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/00034983.1995.11812924","article-title":"Discrimination of Leishmania isolates using a limited set of enzymatic loci","volume":"89","author":"Cupolillo","year":"1995","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.trstmh.2008.09.008","article-title":"Paromomycin","volume":"103","author":"Davidson","year":"2009","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/jac\/dkt318","article-title":"In vitro interaction between paromomycin sulphate and four drugs with leishmanicidal activity against three New World Leishmania species","volume":"69","author":"de Morais-Teixeira","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/14787210.4.2.187","article-title":"Treatment options for visceral leishmaniasis","volume":"4","author":"den Boer","year":"2006","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4269\/ajtmh.16-0811","article-title":"Susceptibility to miltefosine in Brazilian clinical isolates of Leishmania (Viannia) braziliensis","volume":"96","author":"Espada","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib15","series-title":"Laboratory Animal Anaesthesia","author":"Flecknell","year":"2009"},{"key":"10.1016\/j.ijpddr.2020.08.001_bib16","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4269\/ajtmh.17-0760","article-title":"Case report: atypical cutaneous leishmaniasis in a patient with mixed Leishmania guyanensis and Leishmania amazonensis infection","volume":"99","author":"Gosch","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2307\/3285646","article-title":"Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin","volume":"85","author":"Grogl","year":"1999","journal-title":"J. Parasitol."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib18","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00436-014-3835-7","article-title":"Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum","volume":"113","author":"Hendrickx","year":"2014","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib19","doi-asserted-by":"crossref","first-page":"e1664","DOI":"10.1371\/journal.pntd.0001664","article-title":"Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol","volume":"6","author":"Hendrickx","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004118","article-title":"Effectiveness study of paromomycin IM injection (PMIM) for the treatment of visceral leishmaniasis (VL) in Bangladesh","volume":"9","author":"Jamil","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molbiopara.2008.12.007","article-title":"Paromomycin: uptake and resistance in Leishmania donovani","volume":"164","author":"Jhingran","year":"2009","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib22","first-page":"1084","article-title":"Stable transfection of the human parasite Leishmania major delineates a 30-kilobase region sufficient for extrachromosomal replication and expression","volume":"10","author":"Kapler","year":"1990","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib23","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1371\/journal.pntd.0000912","article-title":"Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial","volume":"4","author":"Machado","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib24","first-page":"817","article-title":"The past and present of serum aminotransferases and the future of liver injury biomarkers","volume":"15","author":"McGill","year":"2016","journal-title":"Excli J."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0035-9203(80)90253-9","article-title":"Some methods for the enzymic characterization of Latin-American Leishmania with particular reference to Leishmania mexicana amazonensis and subspecies of Leishmania hertigi","volume":"74","author":"Miles","year":"1980","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib26","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","article-title":"Advances in leishmaniasis","volume":"366","author":"Murray","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2020.08.001_bib27","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1128\/JCM.40.5.1666-1669.2002","article-title":"Real-time PCR for detection and quantitation of Leishmania in mouse tissues","volume":"40","author":"Nicolas","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005635","article-title":"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh","volume":"11","author":"Rahman","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijpddr.2018.04.002","article-title":"Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs","volume":"8","author":"Rastrojo","year":"2018","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mimet.2013.02.007","article-title":"Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: validation of luciferase as a quantitative tool","volume":"93","author":"Reimao","year":"2013","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.ijpddr.2020.08.001_bib31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib32","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.micinf.2007.01.009","article-title":"Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?","volume":"9","author":"Rijal","year":"2007","journal-title":"Microb. Infect."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib33","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41467-017-01664-4","article-title":"Atomic resolution snapshot of Leishmania ribosome inhibition by the aminoglycoside paromomycin","volume":"8","author":"Shalev-Benami","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/trstmh\/trz037","article-title":"What makes mucosal and anergic diffuse cutaneous leishmaniases so clinically and immunopathogically different? A review in Brazil","author":"Silveira","year":"2019","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007253","article-title":"Topical paromomycin for New World cutaneous leishmaniasis","volume":"13","author":"Sosa","year":"2019","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib36","first-page":"548","article-title":"Acute kidney injury: definition, epidemiology, and outcome","volume":"17","author":"Srisawat","year":"2011","journal-title":"Curr. Opin. Crit. Care"},{"key":"10.1016\/j.ijpddr.2020.08.001_bib37","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for Visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib38","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1517\/14656566.6.16.2821","article-title":"Treatment of visceral leishmaniasis","volume":"6","author":"Sundar","year":"2005","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2020.08.001_bib40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0035-9203(94)90106-6","article-title":"Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica","volume":"88","author":"Teklemariam","year":"1994","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib41","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1017\/S0031182016002523","article-title":"Chemotherapy of leishmaniasis: present challenges","volume":"145","author":"Uliana","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2020.08.001_bib42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.exppara.2013.01.022","article-title":"Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model","volume":"134","author":"Utaile","year":"2013","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib43","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","article-title":"Combination therapy for visceral leishmaniasis","volume":"10","author":"van Griensven","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpddr.2018.04.001","article-title":"Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome((R)) and AmBisome((R)) in murine cutaneous leishmaniasis","volume":"8","author":"Wijnant","year":"2018","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00358-17","article-title":"Efficacy of paromomycin-chloroquine combination therapy in experimental cutaneous leishmaniasis","volume":"61","author":"Wijnant","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib46","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1086\/507710","article-title":"American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility?","volume":"194","author":"Yardley","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib47","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/IAI.71.3.1225-1233.2003","article-title":"Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages","volume":"71","author":"Zamboni","year":"2003","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijpddr.2020.08.001_bib48","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.drudis.2017.06.004","article-title":"Leishmaniasis drug discovery: recent progress and challenges in assay development","volume":"22","author":"Zulfiqar","year":"2017","journal-title":"Drug Discov. Today"}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221132072030021X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221132072030021X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:52:13Z","timestamp":1761922333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221132072030021X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":48,"alternative-id":["S221132072030021X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2020.08.001","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2020.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}